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A B S T R A C T
N-terminal proB-type natriuretic peptide (NT-proBNP) is known as a marker of heart failure (HF). NT-
proBNP is also elevated in a patient with atrial ﬁbrillation (AF). In this case report, serial assays of NT-
proBNP were performed in AF attack without HF. We found the positive association between the level of
NT-proBNP and duration of AF attack. This case suggested that secretion of NT-proBNP from left atrium
might be abundant in the case of paroxysmal AF (PAF) or PAF might lead to increasing left ventricle stress
in a time-dependent manner. Moreover, it is suggested that the measurement of NT-proBNP levels
considering the elapsed time after the onset of PAF would be useful.
<Learning objective: Measurement of NT-proBNP levels during PAF attack may be useful to estimate
the duration of PAF attack and degree of left ventricle stress in patients with PAF.>
 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Although N-terminal proB-type natriuretic peptide (NT-
proBNP), a useful marker of heart failure (HF) [1], is considered
to be secreted mainly from the ventricle, increased serum NT-
proBNP levels are also encountered in conditions such as atrial
ﬁbrillation (AF) [2] and atrial septal defect in patients without HF.
It can readily be assumed that the atrium is better suited as a
baroreceptor or volume receptor along with the ventricle. In
general, secretion of NT-proBNP from left atria is about 10% of all
secreted NT-proBNP. If the NT-proBNP level increases sharply at
the onset of paroxysmal atrial ﬁbrillation (PAF) and decreases
immediately after the termination of PAF, the role of the atrium in
the regulation of NT-proBNP secretion will be more clearly
elucidated. We experienced the following case with PAF who
was longitudinally followed-up and analyzed the changes in serum* Corresponding author at: Division of Health Science, Osaka University Graduate
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1878-5409/ 2015 Japanese College of Cardiology. Published by Elsevier Ltd. All rightNT-proBNP levels after PAF onset using accurate blood samples to
clarify the meaning of elevated serum NT-proBNP level in patients
with AF.
Case report
A 62-year-old man with PAF and well-controlled essential
hypertension had eight episodes of PAF attacks between May and
July 2014. Table 1 shows detailed patient information. Since he was
a family physician, all eight episodes of PAF were conﬁrmed by a
single channel monitor electrocardiogram (ECG) and both begin-
ning and ending times were recorded precisely. Of 32 total
measurements of serum NT-proBNP, 21 were obtained during each
PAF attack with precise recording of the attack duration. Any
symptoms and clinical signs of congestive heart failure (CHF) were
not recognized in each PAF attack in this patient, and no signiﬁcant
cardiac disorders were revealed by ultrasound cardiographic
studies before as shown in Table 1. Heart rate (HR) at sinus
rhythm is 70–80 bpm and HR at PAF attack is 85–100 bpm
recorded by single channel monitor ECG. Written consent to
publish the results was obtained from this patient.s reserved.
Table 1 Patient’s information. (All examination data were obtained at period of post onset of PAF.)
62-Year-old/male/height = 186 cm, weight = 76.5 kg (BMI* = 22.1)
[Present illness] Essential hypertension (since 2010), PAF* (since 2012)
[Medication] Valsartan (80 mg), trichlormethiazide (1 mg), warfarin (5 mg)
[Family history] Father: hypertension, atrial ﬁbrillation, cerebral infarction/mother: hypertension
[Cardiac status] NYHA* classiﬁcation I (he can play basketball)
[Vital signs] Blood pressure = 116/76 mmHg, pulse = 72/min (regular), body temperature = 36.4 8C, respiratory rate = 14/min
[Laboratory data] Prothrombin time-international normalized ratio (=2.43) was elongated, but otherwise all the values obtained from complete blood count
and blood chemistry were in normal range
[Chest X-ray] Slightly elevated aortic knob, no pulmonary congestion, normal cardiac contour, CTR* = 44%
[Electrocardiogram] HR* = 76/min, sinus rhythm, no mitral P, deep S(V2–3), poor R(V1–3), tall T(V2–3), no ST–T changes
[Echocardiography] No structural heart diseases or wall motion abnormalities were recognized. LVDd* = 47, LVDs* = 30, IVS* = 10, LVPW*= 9, LAd* = 29/EF* = 65%
[Holter ambulatory electrocardiogram] Total beats = 99,570/24 h; HR = 50–118 (mean HR = 69)/min; more than 1256 SVPCs* (containing occasional APCs* in
a row and several episodes of PAF for 2 min or less/no rapid ventricular responses, nor long cardiac pauses) and few VPCs* in a day
[Ambulatory blood pressure monitoring] (under medication) sBP* = 140–102 (mean = 122/S.D.* = 16.0) mmHg, dBP* = 85–54 (mean = 71/S.D. = 10.2) mmHg;
pulse = 128–65 (mean = 82/S.D. = 12.6)/min
[Treadmill exercise test] (Bruce Shefﬁeld/Stage III/11 METs*) max*HR = 173/min (97% MHR*), max BP = 165/70 mmHg, No ischemic changes were evoked. Several
APCs developed soon after the exercise but no runs
[Multi-detector-row computed tomography] Abnormalities of wall thickness or motion, signiﬁcant coronary stenoses, and thrombi were not elicited
* BMI, body mass index; PAF, paroxysmal atrial ﬁbrillation; NYHA, New York Heart Association; CTR, cardiothoracic ratio; HR, heart rate; LVDd, diastolic left ventricular
dimension; LVDs, systolic left ventricular dimension; IVS, interventricular septal thickness; LVPW, left ventricular posterior wall thickness; LAd, left atrial dimension; EF,
ejection fraction; SVPC, supraventricular premature contraction; APC, atrial premature contraction; VPC, ventricular premature contraction; sBP, systolic blood pressure; S.D.,
standard deviation; dBP, diastolic blood pressure; METs, metabolic equivalents; max, maximum; MHR, target maximal heart rate.
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observed between the PAF duration and serum NT-proBNP levels
(p < 0.0001). The linear regression equation (solid line) was
y = 13.31x + 64.08 (correlation coefﬁcient: r = 0.965) (Fig. 1). After
termination of the PAF attack, the NT-proBNP levels gradually or
rapidly normalized. The decreasing pattern was dependent on
differences in the PAF duration and degree of elevated NT-proBNP
levels (Fig. 2).Fig. 1.
The black circles (*) indicate the NT-proBNP levels measured at 21 time-po
developed at precisely recorded times. Each dashed line connecting the black 
BNP, N-terminal pro-B-type natriuretic peptide; PAF, paroxysmal atrial ﬁbrilDiscussion
This case report clearly demonstrated a strong linear regression
between the PAF attack duration and level of serum NT-proBNP in
a patient with PAF. The PAF duration is closely associated with the
elevation of NT-proBNP although its detailed mechanisms are
unknown. The elevation of NT-proBNP is well-known as a marker
of the severity of CHF. However, if NT-proBNP is simply consideredints after PAF onset. The numbers from to indicate the 8 attacks of PAF that
circles indicates a series of NT-pro BNP levels obtained in 1 episode of PAF. NT-pro
lation.
Fig. 2.
Attack (black and white circles **, duration of 6 h) and Attack (black and white triangles ~~, duration of approximately 60 h), in which the times of the
onset and termination of PAF were clearly identiﬁed, were examined. In both attacks, the NT-pro BNP levels sharply increased over time after PAF onset (black
circles and triangles *~). NT-pro BNP, N-terminal pro-B-type natriuretic peptide; PAF, paroxysmal atrial ﬁbrillation.
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the CHF condition, it is difﬁcult to explain why NT-proBNP levels
increase in cases of PAF with only minimal stress on the ventricle
without CHF. Moreover, ﬁndings in this case report may indicate
that these changes in the serum NT-proBNP level during the PAF
attack are considered to be responding to a more distensible left
atrium. This case suggested that secretion of NT-proBNP from left
atrium might be abundant in the case of PAF or PAF might lead to
increasing left ventricle stress in a time-dependent manner.
Because serum NT-proBNP levels can markedly change not only
before and after a PAF attack but also during PAF episodes, it is
necessary to reconsider the timing and meaning of collection of
blood samples to examine serum NT-proBNP levels in clinical
situations to estimate the duration of PAF attack and degree of left
ventricle stress in patients with PAF. We expect that HF may not
occur in patients with PAF but without other organic disorders likethis patient had. Future studies need to clarify what conditions
could lead to HF in patients with PAF.
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